Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Wolf, D; Anto-Michel, N; Blankenbach, H; Wiedemann, A; Buscher, K; Hohmann, JD; Lim, B; Bäuml, M; Marki, A; Mauler, M; Duerschmied, D; Fan, Z; Winkels, H; Sidler, D; Diehl, P; Zajonc, DM; Hilgendorf, I; Stachon, P; Marchini, T; Willecke, F; Schell, M; Sommer, B; von Zur Muhlen, C; Reinöhl, J; Gerhardt, T; Plow, EF; Yakubenko, V; Libby, P; Bode, C; Ley, K; Peter, K; Zirlik, A.
A ligand-specific blockade of the integrin Mac-1 selectively targets pathologic inflammation while maintaining protective host-defense.
Nat Commun. 2018; 9(1):525-525 Doi: 10.1038/s41467-018-02896-8 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz
Anto Michel Nathaly
Co-Autor*innen der Med Uni Graz
Zirlik Andreas
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Integrin-based therapeutics have garnered considerable interest in the medical treatment of inflammation. Integrins mediate the fast recruitment of monocytes and neutrophils to the site of inflammation, but are also required for host defense, limiting their therapeutic use. Here, we report a novel monoclonal antibody, anti-M7, that specifically blocks the interaction of the integrin Mac-1 with its pro-inflammatory ligand CD40L, while not interfering with alternative ligands. Anti-M7 selectively reduces leukocyte recruitment in vitro and in vivo. In contrast, conventional anti-Mac-1 therapy is not specific and blocks a broad repertoire of integrin functionality, inhibits phagocytosis, promotes apoptosis, and fuels a cytokine storm in vivo. Whereas conventional anti-integrin therapy potentiates bacterial sepsis, bacteremia, and mortality, a ligand-specific intervention with anti-M7 is protective. These findings deepen our understanding of ligand-specific integrin functions and open a path for a new field of ligand-targeted anti-integrin therapy to prevent inflammatory conditions.
Find related publications in this database (using NLM MeSH Indexing)
Animals -
Antibodies, Monoclonal - pharmacology
Binding Sites -
CD40 Ligand - metabolism
Host-Pathogen Interactions - drug effects
Humans -
Inflammation - drug therapy
Inflammation - pathology
Leukocytes - drug effects
Leukocytes - pathology
Macrophage-1 Antigen - metabolism
Male -
Mice, Inbred C57BL -
Molecular Targeted Therapy - methods
Neutrophils - drug effects
Sepsis - drug therapy

© Med Uni Graz Impressum